[18F]THK-5351 PET imaging of tau deposits in neurological disorders
Phase of Trial: Phase III
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Fluorine 18 THK 5351 (Primary)
- Indications Neurodegenerative disorders; Neurological disorders
- Focus Diagnostic use
- 14 Jul 2018 Planned number of patients changed from 140 to 160.
- 11 Apr 2017 Status changed from not yet recruiting to recruiting.
- 13 May 2016 New trial record